ByTrending Posts
Is the OBI Pharma–TegMine Therapeutics ADC Deal the…
Key Highlights 1. Powering the Next-Gen ADC Revolution: OBI’s GlycOBI® Meets TegMine’s TegMiner™The collaboration between Taiwan-based OBI Pharma…
Can AI Reveal the Hidden Biology of Cancer?…
Key Highlights: AI Collaboration to Decode Cancer ComplexityIn a bold step to redefine cancer treatment, Aitia, a leader…
Is Juvenescence’s Acquisition of Ro5 the Key to…
Key Insights Juvenescence Acquires Ro5 to Bolster AI Capabilities in Drug DiscoveryJuvenescence Limited, a clinical-stage AI-enabled biotech company,…
Can AI Turn Biobank Data into Precision Drug…
Key Highlights Transforming Biobanks into AI-Driven EnginesElucidata, a U.S.-India based AI pioneer in life sciences, and Sapien Biosciences,…
How Will Axxam and Molecular Health’s AI-Powered Alliance…
Key Highlights: Strategic Collaboration Targets Early Drug Discovery BottlenecksAnnounced on June 4, 2025, Molecular Health and Axxam have…
Can Clairity’s FDA-Approved AI Breast Cancer Prediction Tool…
Key Highlights: AI-Driven Risk Prediction: A Breakthrough in Preventive OncologyBoston-based Clairity received FDA de novo authorization for Clairity…
MedInvest 2025: How NeuroOne’s AI-Enabled Brain Stimulation and…
Key Highlights: 1. NeuroOne’s Vision: AI for Real-World Neurological DisordersNeuroOne will join MedInvest’s MedTech, AI & Digital Health…
How CareCloud Is Applying AI to Transform Clinical…
Key Highlights CareCloud to Join Elite Healthcare IT Panel at Maxim ConferenceCareCloud, Inc. (Nasdaq: CCLD, CCLDO), a leading…
How Insilico’s AI-Discovered Drug Achieved a Landmark Clinical…
Key Highlights:• Insilico Medicine’s AI-driven drug discovery platform Pharma.AI enabled rapid development of Rentosertib, a novel TNIK inhibitor…
Trending Posts
Latest Stories
Could Arrowhead’s $2.2B+ RNAi Collaboration with Novartis Redefine the Future of Parkinson’s and Synucleinopathies?
Key Highlights Strategic SignificanceFor Arrowhead, the deal represents its largest CNS collaboration to date, validating…
Could Servier’s $450M Fragile X Acquisition Redefine Its Neurology Strategy?
Key Highlights Strategic Fit for ServierThis marks Servier’s first neurology asset acquisition, aligned with its…
Will GSK’s Fluviral Supply Strengthen Canada’s Seasonal Flu Preparedness?
Key Highlights Public Health ImpactAnnual flu vaccination remains the most effective tool to reduce flu-related…
Could Takeda’s Landmark Phase 3 Oveporexton Results Redefine the Standard of Care in Narcolepsy Type 1?
Key Highlights Clinical Breakthroughs Across EndpointsPatients treated with oveporexton demonstrated marked improvements in excessive daytime…
Gallery
